Jean-Yves Blay, MD, PhD

Centre Léon Bérard
Lyon, Rhone-Alpes, France

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 44 - COMBINATION OF MDM2 AND CDK4/6 INHIIBITOR IN PATIENTS WITH ADVANCED WELL AND DE-DIFFERENCIATED LIPOSARCOMA AND OTHERS CANCERS: COHORT ANALYSIS FROM THE MEGAMOST PHASE II BASKET STUDY

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 80 - A PHASE 2/3 STUDY EVALUATING THE EFFICACY AND SAFETY OF UNESBULIN IN ADVANCED LEIOMYOSARCOMA (SUNRISELMS)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 91 - POWER IN NUMBERS: OVERCOMING SARCOMA DATA SCARCITY BY HARMONISING EUROPEAN SARCOMA OBSERVATIONAL REGISTRIES AND EXPLOTING "OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS - OHDSI" TOOLS

  Saturday, November 16, 2024
  1:00 PM – 2:00 PM PST

• Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST